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Wnt5a is involved in activating several noncanonical Wnt signaling pathways, which can inhibit or activate canonical Wnt/
β-catenin signaling pathway in a receptor context-dependent manner. Wnt5a signaling is critical for regulating normal
developmental processes, including stem cell self-renewal, proliferation, differentiation, migration, adhesion, and polarity.
Moreover, the aberrant activation or inhibition of Wnt5a signaling is emerging as an important event in cancer progression,
exerting both oncogenic and tumor suppressive effects. Recent studies show the involvement of Wnt5a signaling in regulating
normal and cancer stem cell self-renewal, cancer cell proliferation, migration, and invasion. In this article, we review recent
findings regarding the molecular mechanisms and roles of Wnt5a signaling in stem cells in embryogenesis and in the normal or
neoplastic breast or ovary, highlighting that Wnt5a may have different effects on target cells depending on the surface receptors
expressed by the target cell.
1. Introduction
Stem cells, including embryonic stem cells and stem cells
identified in adult tissues, have an ability to self-renew and
to generate more differentiated progeny. The embryonic stem
cell is derived from the inner cell mass of the blastocyst, is plu-
ripotent, and can thus generate all the tissues of the body [1].
Stem cells in adult tissues reside in specialized niches, where
they integrate various environmental and intrinsic signaling
inputs that determine cell fate and maintain tissue homeostasis.
Wnt factors are a group of these signaling molecules that
act on stem cells within the stem cell niche to help maintain
their capacity for self-renewal. Wnt factors are known to bind
to different receptors to transduce the canonical signaling
pathway or noncanonical signaling pathway(s) that regulate
diverse biological activities [2, 3]. The canonical Wnt
signaling pathway is initiated when Wnt factors bind to
Frizzled family receptors (Fzd) and low-density lipoprotein
receptor-related protein 5/6 coreceptors (LRP5/6) to form
complexes. This results in the recruitment of Axin and
dishevelled (Dvl) to the plasma membrane and disruption
of the β-catenin degradation complex, leading to accumula-
tion of β-catenin in the cytoplasm, which then translocates
to the nucleus, where it binds to T-cell factor (TCF)/lymphoid
enhancer factor (LEF) family and activates the transcription of
canonicalWnt target genes [4, 5]. In contrast, several Wnt fac-
tors activate β-catenin-independent pathways (noncanonical
Wnt signaling pathways), known as theWnt-Ca2+ pathway or
planar cell polarity (PCP) pathway, which act to direct cell
migration during embryogenesis [6–8].
Nineteen secreted cysteine-richWnt family glycoproteins
havebeen identified inmice andhumans.During earliermam-
malian embryogenesis or maintenance of adult tissue homeo-
stasis, these Wnt factors and their receptors are dynamically
expressed to activate appropriate signaling, to ensure the right
balance between proliferation and differentiation. Perturba-
tion ofWnt signalingwith aberrant expression ofWnt factors,
their receptors, or downstream signaling molecules may lead
to the development of several human cancers [6, 9, 10].
Because the tumor initiation capacity seems to be restricted
to a small population of tumor cells that are endowed with
the capacity for self-renewal and differentiation, they often
are referred to as cancer stem cells (CSCs, or tumor initiation
cells) [11–14]. More importantly, the biology of embryonic
stem cells, normal stem cells, and CSCs is highly interrelated.
This is evident from the fact that molecular signals (e.g., Wnt
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signaling) that define and maintain embryonic stem cell or
adult normal stem cells are often aberrantly activated in
tumor cells.
Amajor focus of this review is the role ofWnt5a signaling
via different surface receptors in the regulation of stem cells
in embryogenesis and in the normal or neoplastic breast
or ovary, as there already are several excellent reviews that
cover aspects of Wnt signaling in colon cancer [14, 15].
We summarized the latest advances on the signaling
pathways that are activated by Wnt5a and that pose a
conundrum for the rational design of drugs aimed at
depleting the CSCs (or tumor initiation cells) within tumors
while sparing the function of normal tissues.
2. Wnt5a Signaling Pathway
Wnt5a is a noncanonical Wnt ligand that is evolutionarily
conserved and plays an important role in development.
Homozygous Wnt5a knockout mice have perinatal lethality
due to developmental defects [16]. Previous studies showed
that Wnt5a can interact with Fzd2 and receptor tyrosine
kinase-like orphan receptor 2 (ROR2) to activate Rac1 in a
β-catenin-independent pathway. More recently, we demon-
strated that Wnt5a induced heterooligermization of receptor
tyrosine kinase-like orphan receptor 1/2 (ROR1/ROR2),
which recruited and activated guanine exchange factors
(GEFs), which in turn activated RhoA and Rac1, respectively,
enhancing leukemia-cell chemotaxis and proliferation [17].
On the other hand, as another action of Wnt5a, it competed
with Wnt3a for binding to Fzd2, thereby inhibiting Wnt3a-
dependent LRP6 phosphorylation and β-catenin accumula-
tion in vitro and in intact cells, inhibiting the capacity of
Wnt3a to induce accumulation of β-catenin, and thereby
inhibiting β-catenin-dependent Wnt signaling [18].
However,Wnt5a also could activate β-catenin-dependent
pathway and induce secondary axis formation in Xenopus
embryos that coexpressed the Fzd5 receptor [19, 20]. Subse-
quently, another study found that Wnt5a could inhibit
canonical Wnt/β-catenin signaling in cells that expressed
ROR2, but also could induce canonical Wnt/β-catenin sig-
naling in cells that expressed Fzd4 and LRP5 [21]. Thus, a
single Wnt5a ligand can have disparate effects on cells
depending on receptor availability. Therefore, the cellular
context dictates the effect of Wnt5a. This might account to
the observation that the Wnt5a could exert either oncogenic
or tumor suppressive effects in different cancers [18, 21–23].
3. Wnt5a Signaling in Embryonic Stem Cells
The Wnt pathway (triggered either by Wnt3a, Wnt5a, or
Wnt6) also could be involved in the short-term mainte-
nance of pluripotency of both mouse and human ES cells
[24]. The first evidence for this was provided by a study of
a pharmacological inhibitor of glycogen synthase kinase-3
(GSK3) that could modulate GSK3 activity, leading to acti-
vation of β-catenin canonical signaling and increased
stability of c-Myc [25, 26]. Wnt5a and Wnt6 subsequently
were found to be produced by embryonic fibroblast feeder
cells, which could inhibit mouse ES cell differentiation in a
serum-dependent manner. Direct activation of β-catenin,
using constitutively active β-catenin (S33Y) without disturb-
ing the upstream components of the Wnt/β-catenin, fully
recapitulated the effect of Wnts on ES cells. Importantly,
Wnt5a also is a potent inhibitor ofβ-catenin phosphorylation,
thereby stabilizing β-catenin [5]. These data suggest that
Wnt5a signals to stabilize β-catenin to further activate
Wnt/β-catenin canonical signaling in mouse ES cells. Finally,
the Wnt/β-catenin pathway can upregulate the mRNA for
STAT3, a known regulator of ES cell self-renewal [27], sug-
gesting a molecular mechanism whereby the Wnt/β-catenin
pathwayacts topreventES cell differentiation through conver-
gence on the LIF/JAK-STAT pathway at the level of STAT3
[28]. However, what surface receptors are involved in the acti-
vation of Wnt5a/β-catenin signaling in ES cells and whether
noncanonicalWnt signaling also could be activated byWnt5a
in ES cells remains unclear.
4. Wnt5a Signaling on Stem Cells in Normal
Mammary Gland and Ovarian Tissues
A line of evidence supports the importance of Wnt in main-
taining of mammary stem cells in mammary gland [29–31].
However, Wnt5a does not induce β-catenin/TCF transacti-
vation activity in mammary gland tissue. The cells of the
mammary gland are hyperproliferative in Wnt5a knockout
mice, whereas in the presence of ectopicWnt5a, ductal exten-
sion is inhibited [32]. These phenotypes are the inverse of the
activation of canonical Wnt/β-catenin signaling. Therefore,
Wnt5a may limit and control mammary gland growth by
suppressing Wnt/β-catenin signaling. It is puzzling then that
this inhibition of mammary gland growth was not observed
in transgenic MMTV-Wnt5a strains [33].
In the Drosophila germarium, altered Wingless (Wg; the
flyWnthomologue) signaling occurs inovarian germline stem
cells (GSCs) through removal of its regulators such as dishev-
elled, armadillo, Axin, and shaggy; this causes GSC loss,
influences follicle cell proliferation, and induces differentia-
tion [34, 35]. Using conditional gene targeting for Wnt5a
inovariangranulosa cells (GC) results in the female subfertility
associated with increased follicular atresia and decreased rates
of ovulation. Further study found that Wnt5a regulates its
target genes not by signaling via the Wnt/Ca2+ or planar cell
polarity pathway, but rather by inhibiting the canonical path-
way, causing both β-catenin and cAMP responsive element
binding (CREB) protein levels to decrease via a glycogen syn-
thase kinase-3β-dependentpathway inovariangranulosa cells
(GC). These data indicate that Wnt5a is required for normal
ovarian follicle development and can antagonize gonadotro-
pin responsiveness in granulosa cells by suppressing canonical
Wnt/β-catenin signaling [36].
Collectively, Wnt5a is most likely to suppress β-catenin
signaling in normal stem cells of mammary gland and ovar-
ian tissues, although Wnt5a is able to activate β-catenin
signaling in embryonic stem cells. Whether this difference
is due to receptors that are differentially expressed in embry-
onic stem cells versus stem cells of normal mammary gland
or the ovary needs to be further investigated.
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5. Wnt5a Signaling in Breast Cancer Stem Cells
Wnt factors may affect various mammary epithelial cells and
induce an expansion of stem cells during tumor progression
[37–42]. Moreover, aberrant β-catenin expression was asso-
ciated with basal, triple-negative breast cancers and poor
clinical outcome [43, 44]. The occurrence of aberrant Wnt
signaling in specific breast cancer subtypes is less likely
dictated by activation caused by somatic mutations. Muta-
tions have not been identified in CTNNB1, which encodes
β-catenin, and mutations within APC have been identified
in less than 20% of breast cancer patient samples [45]. Fur-
ther investigation is needed to determine which Wnt ligands
and receptors cause this aberrant Wnt/β-catenin signaling.
Recently, a study on MMTV-Wnt1 mouse primary cells
found that both recombinantWnt3a and recombinantWnt5a
could enhance formation of mammospheres in vitro. Wnt5a-
induced formation of mammospheres was not caused by an
increase in canonical Wnt/β-catenin signaling, but was
instead mediated by noncanonical Wnt signaling requiring
the receptor tyrosine kinase ROR2 and the activity of the Jun
N-terminal kinase, JNK, inmousebreast cancer cells [46].This
is consistent with the observation that patients with breast
cancers that express ROR2 had a significantly shorter over-
all survival than those with tumors lacking expression of
ROR2 [47]. However, silencing ROR2 in human breast cancer
cell lines decreased both β-catenin-dependent and β-catenin-
independent targets [47], suggesting that ROR2 may be
involved in both β-catenin-dependent and β-catenin-
independent Wnt signaling pathways. ROR1 predominately
seems to be expressed by less well-differentiated tumors that
have high potential for relapse and metastases and that also
express markers associated with epithelial–mesenchymal
transition (EMT) [48, 49]. Conversely, silencing ROR1 in
human breast cancer cell lines could attenuate expression
of genes associated with EMT and impair their migration/
invasion capacity in vitro and their metastatic potential
in vivo [49]. Very recently, Chien et al. reported that ROR1
expressionmight be an independent adverse prognostic factor
in patients with triple-negative breast cancers [50]. Whether
ROR1 can have a similar effect with ROR2 on breast cancer
stem cell and what signaling pathway(s) are activated by
ROR1 in breast cancer stem cells remains unknown.
A study on a mouse model of ErbB2-induced breast can-
cer found conflicting evidence on the effect of Wnt5a on
human breast cancer stem cells. During ErbB2-induced
mammary tumorigenesis, basal tumor-initiating cells (TIC),
which exhibited enhanced tumorigenic capacity compared
with the corresponding luminal progenitors, preferentially
lost Wnt5a expression, as determined by transcript profiling
analysis. Moreover, Wnt5a heterozygosity promoted tumor
multiplicity and pulmonary metastasis. As a TGFβ substrate,
luminal cell-produced Wnt5a induced a feed-forward
loop that activated SMAD2 in a RYK- and TGFβR1-
dependent manner to limit the expansion of basal TIC in
a paracrine fashion, a potential explanation for the sup-
pressive effect of Wnt5a on mammary tumorigenesis [51].
In this mouse model, it remains uncertain whether canon-
icalWnt/β-catenin signaling was activated or ifWnt5a also
inhibited canonical β-catenin signaling to suppress basal
TIC expansion.
The Weinberg laboratory studied immortalized human
mammary epithelial cells (mMECs) and found that both
the canonical and noncanonical Wnt pathways cooperated
with TGFβ signaling in not only the maintenance, but
intriguingly also the induction, of stem cell properties [52].
Moreover, only noncanonical Wnt ligands Wnt5a and
Wnt16 were found upregulated in stem-like cells relative to
non-stem-like cells [52]. Therefore, it is possible that Wnt5a
or Wnt16 may activate either the canonical or noncanonical
Wnt signaling pathway in a receptor context-dependent
manner in human breast cancer stem cells.
6. Wnt5a Signaling inOvarianCancer StemCells
Similar to breast cancer, Wnt5a effect on ovarian cancer is
also controversial. An early study of primary ovarian tumors
(n = 130) that showed low levels of Wnt5a in ovarian cancer
relative to normal ovary is predictive of a poor outcome [53].
Ectopic expression of Wnt5a inhibits the proliferation of
human ovarian cancer cell line OVCAR5 both in vitro and
in vivo orthotopic ovarian cancer mouse models. Mechanis-
tically, ectopic expression of Wnt5a in OVCAR5 antagonizes
canonical Wnt/β-catenin signaling and induces cellular
senescence by activating the histone repressor A (HIRA)/
promyelocytic leukemia (PML) senescence pathway [53].
In contrast, studies involving a large number of patients
found that upregulation of Wnt5a was associated with a
relatively poor prognosis [54–58]. Compared with the
frequency of Wnt1 expression in ovarian cancer, Wnt5a
was more frequently found in malignant epithelial ovarian
cancer patients (80% out of a total 38) [54]. Of note, patients
with ovarian cancers that express high levels of both Wnt1
and Wnt5a had a significantly lower probability of long-
term survival than patients with ovarian cancers that did
not express Wnt1 or Wnt5a. Furthermore, Wnt5a is preva-
lent in ascites fluid obtained from women with ovarian can-
cer [55], suggesting that it contributes to the ovarian tumor
microenvironment. This is consistent with the observation
that high levels of Wnt5a are associated with increased risk
for metastasis [55].
Activating mutations in the canonical Wnt pathway is
rare in ovarian cancer, with the exception of endometrioid
ovarian cancers [59]. The contribution of canonical Wnt sig-
naling to progression of ovarian cancer remains unknown.
Conversely, studies on noncanonical Wnt/β-catenin signal-
ing show that Wnt5a may regulate ovarian cancer EMT,
migration, or metastasis via noncanonical signaling path-
ways [57, 60]. Consistent with this notion, recent studies
have found that expression of ROR1, a receptor of Wnt5a,
was highly expressed by high-grade and less-differentiated
ovarian cancers and associated with a relatively short
disease-free survival and overall survival compared to ovarian
cancers that did not express ROR1 [61–63]. Ovarian cancers
that express high levels of ROR1 had gene expression
signatures associated with ovarian CSCs [62]. Furthermore,
tumor-cell expression of ROR1 apparently correlates with
the expression of ALDH1 and the capacity to form tumor
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spheroids in vitro (both markers of CSC). Treating primary
ovarian patient-derived xenograft (PDX) tumor cells,
which express high levels of ROR1 with an anti-ROR1 mAb
(UC-961 or cirmtuzumab), inhibited spheroid formation
and migration in vitro and engraftment and re-engraftment
in immune-deficient mice, indicating that ROR1 may
influence ovarian cancer stem cell self-renewal. Further
studies are needed to determine if Wnt5a is responsible for
the influence that ROR1 apparently has on the biology of
ovarian cancer stem cells.
7. Concluding Remarks
Wnt5amay play an important role in embryonic stem cell and
organ development. However, the role of Wnt5a in cancer
stem cells is varied and complex. It may suppress or promote
tumor progression. To elucidate molecular mechanisms that
drive altered cellular behavior, additional research on tissue-
specific expression of specific receptors and coreceptors is
needed. In particular, a more detailed understanding of the
complex cross-talk betweenWnt5a and specific receptors that
are expressed in embryonic stem cells and that may be re-
expressed or reactivated in cancer stemcells, but not innormal
somatic tissues (e.g., ROR1 and ROR2), may enable develop-
ment of specific inhibitors that block aberrant signaling and
thereby favorably impact patient survival.
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